Published on 03/12/2025
Network Governance for E&L: Re-Use, Exceptions, and Periodic Review
Introduction to Extractables and Leachables (E&L)
In the pharmaceutical industry, extractables and leachables (E&L) testing is critical in ensuring product safety and efficacy. E&L are the chemical compounds that can be extracted from packaging materials and subsequently leach into drug products, which may impact patient safety. The US FDA, EMA, and MHRA have outlined stringent requirements for E&L testing, focusing on reducing risks associated with these contaminants.
This tutorial provides a step-by-step guide on employing network governance for E&L, focusing on aspects such as re-use practices, exceptions, and the periodic review process. By following these guidelines, pharmaceutical professionals can ensure that E&L testing meets regulatory expectations while maintaining a robust quality management system (QMS).
Understanding E&L Risk Assessment
Effective E&L risk assessment is a fundamental part of ensuring that pharmaceutical products are safe for patient administration. The assessment involves identifying potential risks associated with extractables and leachables and determining their impact based on specific product characteristics and intended use. This process must be aligned with the analytical evaluation threshold (AET) and the dose-based threshold (DBT).
Step 1: Begin with a comprehensive literature review. Research existing studies and data on extractables and leachables relevant to the materials used in your packaging system.
Step 2: Identify the materials of construction for your container closure systems (CCS). Note especially if your product is packaged in single-use systems, as these often introduce unique E&L challenges.
Step 3: Apply a risk-based approach by selecting materials based on the quantity and nature of their use. Employ the PQRI guideline as a baseline reference for acceptable limits of extractables and leachables.
The risk assessment must consider different types of products, their dosage forms, administration routes, and demographic factors relevant to patient populations. Consulting and collaboratively working with stakeholders across the product lifecycle is vital for this phase.
AET and DBT Calculations for E&L
Setting thresholds for extractables and leachables is essential in managing the associated risks. The analytical evaluation threshold (AET) and the dose-based threshold (DBT) serve as key metrics for establishing acceptable limits for E&L substances in drug products.
AET Calculation: The AET is defined as the concentration of leachables that must be evaluated analytically to ensure safety. The formula for AET is generally determined by the product’s typical dose and the maximum acceptable daily exposure (ADE). A process begins with determining the highest daily dose and calculating the threshold as part of the E&L risk management strategy.
DBT Calculation: The DBT, on the other hand, considers the actual patient exposure to the drug product. This calculation involves using the acceptable limits of daily exposure that can be administered to patients without adverse effects. It integrates patient weight and the acceptable concentration of leachables.
Step 1: Establish the maximum daily dose of the finished drug product.
Step 2: Utilize the following simplified formulas:
- AET = (Daily Dose x %Extractable) / Total Volume of the Container
- DBT = ADE / Patient Weight
Step 3: After these calculations, compare your results against established regulatory thresholds from standards such as USP and other relevant guidelines.
By ensuring accurate AET and DBT calculations, you will be better prepared for regulatory scrutiny and can solidify your E&L compliance efforts.
Container Closure Integrity (CCI) Testing
Container closure integrity (CCI) testing is paramount in safeguarding drug products from contamination and ensuring the effectiveness of packaging systems. For both terminally sterile and non-sterile products, CCI testing verifies that barriers remain intact throughout the product’s lifecycle.
Step 1: Determine the appropriate CCI test methods based on the drug product’s characteristics and intended use. Popular CCI methods include:
- Vacuum Decay Testing
- Helium Leak Testing
- Microbial Challenge Testing
Step 2: Implement routine CCI testing during the product development phase and before regulatory submission. Regular testing helps identify any potential failure points in the container closure systems.
Step 3: Document all testing procedures, results, and any required corrective actions. Consistent documentation is vital for regulatory compliance and ensures a clear audit trail should investigations occur.
High-stakes drug products often require comprehensive CCI validation strategies, particularly those related to single-use systems, where consistent integrity is crucial.
Periodic Review and Re-evaluation of E&L Data
Periodic reviews of E&L data ensure continuous compliance with evolving regulatory standards and advancements in testing methodologies. You should have a system in place for promptly re-evaluating E&L data in light of new research, regulatory guidance, or product changes.
Step 1: Establish a schedule for periodic review based on the volatility of materials, product changes, or a fixed timeline (e.g., annually). Regular intervals will help ensure that E&L testing remains relevant and compliant with current regulations.
Step 2: Use a multi-disciplinary approach during reviews that may include product development, regulatory affairs, and quality assurance representatives. This collaborative process allows for a comprehensive assessment of ongoing E&L risks.
Step 3: Ensure that any findings from the periodic reviews are documented, and any necessitated updates to testing protocols or threshold parameters are implemented systematically.
Adjustments may be necessary for risk assessment parameters if substantial findings are discovered during periodic evaluations, underscoring the need for proactive quality management.
Conclusion and Best Practices in E&L Governance
Effective network governance for E&L involves continuous, deliberate methodologies that incorporate regulatory guidelines established by authorities such as the FDA, EMA, and MHRA. By adhering to these guidelines, pharmaceutical companies can safeguard product quality and patient safety while achieving compliance with the required analytical evaluation thresholds and container closure integrity.
As regulatory expectations continue evolving and methodologies improve, the pharmaceutical industry must remain vigilant in applying these best practices within their validation frameworks. Implementing a robust validation process that encompasses E&L risk assessments, thorough CCI testing, and regular review cycles will ensure readiness for inspections and optimize product safety.
For further reading and exact regulatory references, consult the FDA’s guidance documents on E&L testing and the USP’s guidelines on container closure integrity testing.